Techlab, Inc.

Other

Virginia Tech Intellectual Properties Inc

Research, Incorporated

Virginia Polytechnic Institute and State University

American Red Cross

Virginia Intellectual Property Division

Tracy Dale Wilkins

David Maxwell Lyerly

James Hunter Boone

Richard Littleton Guerrant

Carol J Phelps

Limin Zheng

J Scott Moncrief

William N Drohan

William Hugold Velander

John L Johnson

Robert J Carman

Nadine Michele Sullivan

Manli Y Davis

Janice E Buss

Kenneth D Tucker

Franklin Jimenez-Ulate

Howard C Krivan

James H Boone

disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases ofare treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence ofdisease is detected using a biomarker panel that includesantigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected ofdisease, if GDH is detected indicating the presence of, and then toxins A and/or B are detected to indicate toxigenicand support a diagnosis of-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.

[object Object]

Accurate and fast detection of the presence ofdisease is important for the proper treatment of patients withinfection. Present tests depend upon culture of viable bacteria and identification by microscopy, which requires care, skill, and two or more days for conclusive results. The current invention improves the ease of use and overcomes the limitations of loss of viability and delay inherent inbacterial culture and provides a more rapid alternative for the identification and diagnosis ofand campylobacteriosis. The invention provides a new method of detectingby utilizing an outer membrane protein (OMP 18) to develop antibodies for use in immunoassays of bacterial cultures or human fecal samples.

Outer membrane protein 18 as a diagnostic marker for campylobacter

The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.

Device and method for detection of analytes

Accurate and fast detection of the presence of() disease is crucial for the proper treatment of patients withinfection. Present tests detecting the presence ofdisease are fast and cost effective, but are not very sensitive. Using an ELISA including Cell Wall Protein 84 (Cwp84) increases the sensitivity of the ELISA. Cwp84 may be used alone or in combination with other markers to support a diagnosis of-associated disease.

The invention provides materials, compositions, methods, and kits for deterring or repelling animals from eating plant materials. The invention relates to the use of particulate matter to deter animals from eating plant materials that are susceptible to grazing by animals. In exemplary embodiments, an adhesive is applied to target plant material and the particulate matter is then applied prior to curing or drying of the adhesive.

Animal deterrent for protecting plants

A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.

Method for diagnosing irritable bowel syndrome and monitoring inflammatory bowel disease

A method for the differentiation of inflammatory bowel disease (IBD) from irritable bowel disease (IBS) followed by distinguishing ulcerative colitis and Crohn's disease from other gastrointestinal illnesses. This highly differential method first uses the presence of elevated lactoferrin as a marker of intestinal inflammation to differentiate IBD from IBS. Patients suspected of IBD are then analyzed for fecal anti-antibodies (ASCA) as an indicator of Crohn's disease and fecal anti-neutrophil cytoplasmic antibodies (ANCA) as an indicator of ulcerative colitis. IBD patients are further monitored for intestinal inflammation using fecal lactoferrin to evaluate the effectiveness of medical therapy and to predict relapse. The apparatus comprises either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous lactoferrin, ASCA and ANCA in human feces. The method and apparatus can be used by healthcare providers to identify IBD and distinguish ulcerative colitis from Crohn's disease.

Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel

A method and apparatus for the differentiation of ulcerative colitis from Crohn's disease and other gastrointestinal illnesses using the presence of anti-neutrophil cytoplasmic antibodies (ANCA) as a marker of ulcerative colitis is described. The apparatus consists of either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobulins for the measurement of total endogenous ANCA in a human sample. The method and apparatus can be used by healthcare providers to distinguish ulcerative colitis from Crohn's disease and other gastrointestinal illnesses.

Method for distinguishing ulcerative colitis from Crohn's disease by detecting the presence of fecal anit-neutrophil cytoplasmic antibodies (ANCA)

Method for monitoring gastrointestinal inflammation in persons with inflammatory bowel disease(IBD)

Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker

The present invention relates to the field of medical immunology and further to pharmaceutical compositions, methods of making and methods of use of vaccines. More specifically this invention relates to recombinant proteins derived from the genes encodingtoxin A and toxin B, and their use in an active vaccine against

Methods to produce high levels of C. difficile toxins

A method and apparatus for the differentiation of Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome, using the presence of fecal anti-antibodies (ASCA) as a marker for Crohn's disease are provided. The apparatus includes an enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous ASCA in a human fecal sample. The method and apparatus may be used by healthcare providers to distinguish Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome.

Method and apparatus for distinguishing Crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to Saccharomyces cerevisiae

The present invention relates to the field of medical immunology and further to pharmaceutical compositions, methods of making and methods of use of vaccines. More specifically this invention relates to recombinant proteins derived from the genes encoding toxin A and toxin B, and their use in an active vaccine against

Growing community of inventors

Riner, VA, United States of America

Tracy Dale Wilkins